Editorial
Atezolizumab: state of art and future perspective in non-small cell lung cancer treatment
Abstract
Lung cancer is the first cause of cancer deaths worldwide (1). Nowadays, treatment landscape of non-small cell lung cancer (NSCLC) is rapidly changing by the introduction of immune-checkpoint inhibitors (2,3).
